Table 3 Percentage of cases with cytoplasmic immunostaining categorized in no expression, and weak, moderate, or strong intensity of CaV1.1, CaV1.2 and CaV1.3 immunostaining in all analysed regions. Cytoplasmic immunoexpression is seen for all channels in most cases of all regions
No expression | Weak | Moderate | Strong | |||
|---|---|---|---|---|---|---|
C Y T O P L A S M I C | 1.1 | Breast without alteration | 18.1% (2/11) | 45.4% (5/11) | 36.3% (4/11) | 0.0% (0/11) |
Ductal hyperplasia | 10.0% (1/10) | 50.0% (5/10) | 40.0% (4/10) | 0.0% (0/10) | ||
Ductal carcinoma in situ | 33.3% (1/3) | 66.6% (2/3) | 0.0% (0/3) | 0.0% (0/3) | ||
Invasive breast carcinoma of no special type | 16.6% (1/6) | 66.6% (4/6) | 16.6% (1/6) | 0.0% (0/6) | ||
1.2 | Breast without alteration | 0.0% (0/10) | 60% (6/10) | 40% (4/10) | 0.0% (0/10) | |
Ductal hyperplasia | 0.0% (0/11) | 63.6% (7/11) | 27.2% (3/11) | 9.0% (1/11) | ||
Ductal carcinoma in situ | 0.0% (0/5) | 80.0% (4/5) | 20.0% (1/5) | 0.0% (0/5) | ||
Invasive breast carcinoma of no special type | 0.0% (0/3) | 33.3% (1/3) | 66.6% (2/3) | 0.0% (0/3) | ||
13 | Breast without alteration | 9.0% (1/11) | 36.3% (4/11) | 45.4% (5/11) | 9.0% (1/11) | |
Ductal hyperplasia | 8.3% (1/12) | 66.6% (8/12) | 25% (3/12) | 0.0% (0/12) | ||
Ductal carcinoma in situ | 33.3% (2/6) | 50.0% (3/6) | 16.3% (1/6) | 0.0% (0/6) | ||
Invasive breast carcinoma of no special type | 0.0% (0/6) | 50.0% (3/6) | 50.0% (3/6) | 0.0% (0/6) |